Research firm Worldpanel by Numerator said on Thursday that the impact of weight-loss medications on UK grocery spending has exceeded £1 billion (about $1.32 billion), and usage of these drugs is accelerating further with the arrival of new oral weight-loss treatments and a steadily expanding male user base.
According to Worldpanel, in the UK, households where someone uses GLP-1 drugs spent more than £1 billion less on total groceries in the year after starting the medication compared with households with no users.
The share of UK households using GLP-1 drugs, such as Eli Lilly's Mounjaro or Novo Nordisk's Wegovy, has risen from 6.3% in February this year to 8.5% in August. That growth is accelerating. Over the past six months, the increase in users of GLP-1 injections and oral medications has been almost equivalent to the total growth of the entire previous year. Although the related oral drug was only approved for market launch in June, it already accounts for 11.2% of total UK GLP-1 users. Male users are also one of the drivers of growth, with their share rising from 23% in February to 32%.
Worldpanel by Numerator is a global consumer data company. Its survey data on UK household purchasing behavior is based on a total sample of 9,629.
The reduction in UK grocery market spending due to GLP-1 drug use amounts to as much as £1 billion, equivalent to a decrease of £389 in annual shopping expenditure for each relevant user household. Compared with non-user households, user households spent 15% more less on alcoholic beverages and potato chips. By contrast, convenient and portion-controlled products are increasingly favored; user households increased their purchases of frozen ready meals by 30%. According to Worldpanel estimates, by 2027, the share of UK households using GLP-1 drugs is expected to exceed 10%.
Comments